Skip to main content
German Center for Infection Research
  • Research
    • Back
    • Bridging Topics
    • Research Areas
    • Infrastructures
    • Working Groups
    • Projects
    • African Partner Institutions
    • Clinical Trials
    • Publications
  • Translation
    • Back
    • Developing Medication
    • Successful Translation
    • Collaborations
    • German Centers for Health Research
  • DZIF Academy
  • Newsroom
    • Back
    • News
    • Media Centre
    • Press Office
    • Events
    • Jobs
  • About us
    • Back
    • Portrait
    • DZIF Structure and Bodies
    • Partner Sites
    • Executive Board
    • DZIF Patient Advisory Board
    • Staff
    • Main Office
    • Donations
  • De
  • |
  • En

Prof. Dr. Anna Hirsch

Breadcrumb

  1. Home
  2. About Us
  3. Staff
  4. Prof. Dr. Anna Hirsch
Contact
Anna Hirsch

Prof. Dr. Anna Hirsch

Telefonnummer +49 681 98806 2001
E-Mail Send mail
Partner Site
Hannover - Braunschweig
Institution
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
Helmholtz Centre for Infection Research
Research Area
Novel Antibiotics

Research of the employee

Bonn - Köln | Hannover - Braunschweig

Optimization of chlorotonils towards an orally available treatment

This project prepares the preclinical development of the semi-synthetic chlorotonil derivative dehalogenil for the treatment of bacterial infections caused by Gram-positive pathogens. Dehalogenil impresses with its potent and very rapid antibacterial effect, which is triggered by membrane depolarization and potassium efflux. Further studies on the mechanism of action have revealed [...]

Read more
Hannover - Braunschweig | Tübingen

Investigating the repertoire of Pseudomonas aeruginosa virulence factors in nosocomial pneumonia

Pseudomonas aeruginosa is a hospital-acquired pathogen that causes difficult-to-treat infections, especially when caused by antibiotic-resistant isolates. There is a high unmet medical need, particularly for pneumonia, which often progresses to severe disease with high morbidity and mortality despite adequate antibiotic treatment. In order to increase the translational reach of the [...]

Read more
Hannover - Braunschweig

Development of corramycin as an antibiotic against Gram-negative bacteria

Gram-negative bacteria are naturally insensitive to many antibiotics due to their additional outer membrane. In addition, the bacteria have acquired resistance to clinically used antibiotics in recent decades, resulting in multidrug-resistant bacteria. Novel classes of antibiotics are needed to counteract these existing resistance mechanisms. However, no new antibiotic class against [...]

Read more
Bonn - Köln | Hamburg - Lübeck - Borstel - Riems | Hannover - Braunschweig | Tübingen

PAFAP—Pseudomonas aeruginosa-focused anti-infectives pipeline

In the current WHO list of bacterial priority pathogens (WHO BPPL 2024), the World Health Organisation classifies carbapenem-resistant Pseudomonas aeruginosa bacteria as a high-priority pathogen, which means there is an urgent need for new anti-infectives to combat this problematic bacterium. To address this need, the PAFAP project has brought together a [...]

Read more
Hannover - Braunschweig

Preclinical development of Amidochelocardins

The challenge of antibiotic drug development today is the discovery and optimisation of novel bioactive compounds that do not show cross-resistances with clinically applied antibiotics, ideally due to a novel mode of action (MoA) which adresses unexploited microbial targets. In the case of chelocardin, this antibiotic substance was identified several [...]

Read more

Publications of the employee

Sep 2024
ACS Omega

Target-Directed Dynamic Combinatorial Chemistry Affords Binders of Mycobacterium tuberculosis IspE

Autoren
Braun-Cornejo M et al.
Go to publication
Aug 2024
Trends Microbiol

The HIPS 2024 symposium: highlighting advances in pharmaceutical sciences in infection research

Autoren
Mayoka G et al.
Go to publication
Aug 2024
Chem Sci

Isocyanides inhibit bacterial pathogens by covalent targeting of essential metabolic enzymes

Autoren
Geißler A et al.
Go to publication
All publications
  • Share on
    • LinkedIn
Print

Sitemap

  • Research
  • Translation
  • DZIF Academy
  • Newsroom
  • About us

At one click

  • Jobs
  • Media Centre
  • Press releases
  • Press contact
  • Glossary
  • Donations

Newsletter Subscription

Contact

Main Office of the DZIF e. V.
Inhoffenstraße 7
38124 Braunschweig
​

E-Mail Send mail

Fußbereichsmenü

  • DZIF Portal (internal)
  • Imprint
  • Privacy policy
  • Log in
  • Manage cookie consent
German Centers for Health Research
Supported by the Federal Ministry of Education and Research and the participating federal states